http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sat, 13 Jun 2026 04:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Hot+List/Why+does+Barclays+say+it%E2%80%99s+time+to+buy+this+Spanish+stock%3F/26642770.html <p>Regulatory and policy uncertainty in the U.K., a softer trade and economic backdrop in Mexico, and credit quality and loan growth concerns in Brazil have given investors pause. But Barclays’ recent note identifies a Spanish stock ready to navigate this environment with its unique advantages of diversification, cost flexibility and self-help levers.</p><p>Barclays believes it is time to buy Banco Santander SA (BME: SAN) (NYSE: SAN). Firm analysts say current concerns do not justify a materially cautious view on its “earnings outlook, the achievability of its 2028 targets or the investment case.”</p><p>SAN is rated Overweight with a price target of €12.90 http://www.streetinsider.com/Hot+List/Why+does+Barclays+say+it%E2%80%99s+time+to+buy+this+Spanish+stock%3F/26642770.html Sat, 13 Jun 2026 04:00:00 -0400 SAN http://www.streetinsider.com/Hot+List+Pro/Why+does+Barclays+say+it%E2%80%99s+time+to+buy+this+Spanish+stock%3F/26642770.html <p>Regulatory and policy uncertainty in the U.K., a softer trade and economic backdrop in Mexico, and credit quality and loan growth concerns in Brazil have given investors pause. But Barclays’ recent note identifies a Spanish stock ready to navigate this environment with its unique advantages of diversification, cost flexibility and self-help levers.</p><p>Barclays believes it is time to buy Banco Santander SA (BME: SAN) (NYSE: SAN). Firm analysts say current concerns do not justify a materially cautious view on its “earnings outlook, the achievability of its 2028 targets or the investment case.”</p><p>SAN is rated Overweight with a price target of €12.90 http://www.streetinsider.com/Hot+List+Pro/Why+does+Barclays+say+it%E2%80%99s+time+to+buy+this+Spanish+stock%3F/26642770.html Sat, 13 Jun 2026 04:00:00 -0400 SAN http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html <p align="justify"><i>Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes</i></p> <ul type="disc"><li style="margin-top:0.15pt; text-align:justify;">Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to delay the decline in endogenous insulin production </li><li style="text-align:justify;">Approval based on the PROTECT phase 3 study and additional data from the global clinical development program from over 900 patients who received Tzield</li></ul> <p align="justify"><b>Paris, June 13, 2026. </b>The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi%E2%80%99s+Tzield+approved+in+the+US+as+the+first+disease-modifying+therapy+for+patients+recently+diagnosed+with+stage+3+type+1+diabetes/26642398.html Fri, 12 Jun 2026 18:09:00 -0400 A.06822034 A.22211465 A.50215358 O.00356206 O.20026344 O.54450828 O.71462702 SAN SNY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BANCO+SANTANDER+CHILE+++++For%3A+May+31/26639949.html si-local-file:///var/storage/secattach/20260612/26639949.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BANCO+SANTANDER+CHILE+++++For%3A+May+31/26639949.html Fri, 12 Jun 2026 13:35:00 -0400 BSAC BSANTANDER O.00907564 O.03566778 SAN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BANCO+SANTANDER+CHILE+++++For%3A+May+31/26639949.html si-local-file:///var/storage/secattach/20260612/26639949.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BANCO+SANTANDER+CHILE+++++For%3A+May+31/26639949.html Fri, 12 Jun 2026 13:35:00 -0400 BSAC BSANTANDER O.00907564 O.03566778 SAN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BANCO+SANTANDER+CHILE+++++For%3A+May+31/26639949.html si-local-file:///var/storage/secattach/20260612/26639949.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BANCO+SANTANDER+CHILE+++++For%3A+May+31/26639949.html Fri, 12 Jun 2026 13:35:00 -0400 BSAC BSANTANDER O.00907564 O.03566778 SAN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BANCO+SANTANDER+CHILE+++++For%3A+May+31/26639949.html si-local-file:///var/storage/secattach/20260612/26639949.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BANCO+SANTANDER+CHILE+++++For%3A+May+31/26639949.html Fri, 12 Jun 2026 13:35:00 -0400 BSAC BSANTANDER O.00907564 O.03566778 SAN http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BANCO+SANTANDER+CHILE+++++For%3A+May+31/26639949.html si-local-file:///var/storage/secattach/20260612/26639949.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BANCO+SANTANDER+CHILE+++++For%3A+May+31/26639949.html Fri, 12 Jun 2026 13:35:00 -0400 BSAC BSANTANDER O.00907564 O.03566778 SAN